Dr Reddy's recalls over 4,000 bottles of drug in US due to packaging error

Dr Reddy's Laboratories is recalling over 4,000 bottles of a generic drug in the US due to a packaging error. The Hyderabad-based drug major is recalling 4,320 bottles of Tacrolimus Capsules which are used to prevent the body from rejecting a transplanted organ. New Jersey-based Dr Reddy's Laboratories Inc, a unit of the company, is recalling the affected lot due to "Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules," USFDA said in its latest Enforcement Report. The affected lot was produced at the company's Bachupally-based manufacturing plant and marketed in the US by its American arm. Dr Reddy's initiated the Class II nationwide recall on February 8 this year. As per USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remot
07-03-2023

Dr Reddy's improves growth prospects in US with Mayne deal

The transaction's cash consideration is $90 million plus contingent payments up to $15 million. This means enterprise value to sales of nearly 1x.
28-02-2023
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Intimation - Schedule of Analyst / Institutional Investor Meetings
28-02-2023
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Dr. Reddy''s Laboratories announces agreement to acquire Mayne Pharma's U.S. generic prescription product portfolio
27-02-2023

Dr Reddy's Labs trades lower despite robust Q3 as Credit Suisse flags EBITDA worries

According to Credit Suisse, Suboxone still constitutes about 7 percent of Dr Reddy's Labs' base EBITDA, and the entry of Apotex could potentially impact 40 percent of DRL's EBITDA from Suboxone or 3 percent of consolidated EBITDA.
17-02-2023
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

Allotment of Equity Shares on exercise of Stock Options under ESOPs
16-02-2023
Bigul

Explore what tech can do for pharma industry: G V Prasad

IT can play a big role in reducing huge time lags in drug discovery, says MD, Dr Reddy's Laboratories
09-02-2023
Bigul

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Dr. Reddy's included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global's Sustainability Yearbook for the 3rd year
08-02-2023
Bigul

Dr Reddy's Chairman Satish Reddy bags ICT award

The fellowship was delivered at ICT's 4th edition of Biosimilar Workshop
03-02-2023
Next Page
Close

Let's Open Free Demat Account